A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug.
British journal of pharmacology • Vol. 177, Issue 4 • 2020
Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic.
Antioxidants & redox signaling • Vol. 28, Issue 16 • 2018
International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of HS Levels: HS Donors and HS Biosynthesis Inhibitors.
Pharmacological reviews • Vol. 69, Issue 4 • 2017
ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo.
Pharmacological research • Vol. 114 • 2016
